Tokyo (September 4, 2002) Eisai Medical Research Inc. (Headquarters: New Jersey, President: Mindell Seidlin), a U.S. clinical research company of Eisai Co., Ltd. (Headquarters: Tokyo, President: Haruo Naito) has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for ARICEPT (donepezil hydrochloride tablets) for the treatment of vascular dementia (VaD). ARICEPT is currently approved for the symptomatic treatment of Alzheimer's disease.
VaD is second only to AD as the most common form of dementia in most parts of the world. VaD, cognitive decline most commonly caused by a single, localized stroke or series of strokes, accounts for up to 20 percent of all diagnosed dementia cases in the United States and generally begins after age 70. Currently, approximately 1.3 million patients suffer from VaD.
ARICEPT is an acetylcholinesterase inhibitor and was synthesized by Eisai Co., Ltd. ARICEPT increases a neurotransmitter in the brain, acetylcholine, as a treatment for mild to moderate dementia of the Alzheimer's type. Currently ARICEPT has been launched in over 60 counties worldwide including Japan, the United States, the United Kingdom, Germany, and France. Sales are forecast for this fiscal year to be approximately 112.5 billion.